Viramune Xr Oral Tablet, Extended Release 100Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Viramune XR: Oral tablet, extended release (100mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

NEVIRAPINE (ne VYE ra peen) is an antiretroviral medicine. It is used with other medicines to treat HIV. This medicine is not a cure for HIV. It will not stop the spread of HIV to others.

CVS Pharmacy Patient Statistics for Viramune XR: Oral tablet, extended release(100mg)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Viramune XR 100mg Extended-Release Tablet

NDC: 005970129
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Human Immunodeficiency Virus (HIV) Infection

Storage Information
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Viramune XR 100mg Extended-Release Tablet

Reported Side Effects for Viramune XR 100mg Extended-Release Tablet

Elevated Hepatic Enzymes Incidence:
<9.0%*
Severity: MODERATE
Onset: DELAYED
Anemia Incidence:
<7.0%*
Severity: MODERATE
Onset: DELAYED
Loose Stools Incidence:
<2.0%*
Severity: MILD
Onset: EARLY
Tired Incidence:
<5.0%*
Severity: MILD
Onset: EARLY
Muscle Pain Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Low Platelet Count Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Stomach Pain Incidence:
<2.0%*
Severity: MILD
Onset: EARLY
Headache Incidence:
1.0-4.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
1.0-9.0%*
Severity: MILD
Onset: EARLY
Low White Blood Cells Incidence:
2.0-13.0%*
Severity: MODERATE
Onset: DELAYED
High Bilirubin Level Incidence:
2.0%*
Severity: MODERATE
Onset: DELAYED
Vomiting Incidence:
2.0-3.0%*
Severity: MILD
Onset: EARLY
Skin Rash Incidence:
2.0-21.0%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
2.0-3.0%*
Severity: MILD
Onset: DELAYED
Yellow Skin Incidence:
2.0-3.0%*
Severity: MODERATE
Onset: DELAYED
High Cholesterol Incidence:
22.0%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Viramune XR 100mg Extended-Release Tablet

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Moderate Lifestyle Interaction
Marijuana and Viramune XR 100mg Extended-Release Tablet(Nevirapine)
Marijuana and Non-nucleoside reverse transcriptase inhibitors(Nevirapine)
Although an interaction is possible, these drugs may be used together. In therory, side effects from Marijuana, Medical may get worse if you take Anti-retroviral non-nucleoside reverse transcriptase inhibitors (NNRTIs). However, the importance of this interaction is not known. Notify your health care provider if you notice increased fatigue, nausea, vomiting, or any other unusual effects.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Viramune XR

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5